Entity

Time filter

Source Type

Hayward, CA, United States

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. A-623 is Anthera’s leading drug candidate which is being developed for treatment of both systemic lupus erythematosus and IgA nephropathy. Wikipedia.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gs23vh/glomerulonephritis) has announced the addition of the "Glomerulonephritis Global Clinical Trials Review, H1, 2015" report to their offering. Glomerulonephritis Global Clinical Trials Review, H1, 2015" provides data on the Glomerulonephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glomerulonephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glomerulonephritis.


News Article | July 27, 2015
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/grpt7c/ascites_global) has announced the addition of the "Ascites Global Clinical Trials Review, H1, 2015" report to their offering. "Ascites Global Clinical Trials Review, H1, 2015" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ascites. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gdw7kx/exocrine) has announced the addition of the "Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


News Article | July 1, 2015
Site: www.businesswire.com

Please contact us via phone if you have a press release scheduled or if you are preparing to send in a release so that we can advise you further. Thank you.


Rosenson R.S.,Mount Sinai School of Medicine | Hislop C.,Anthera Pharmaceuticals | Elliott M.,Anthera Pharmaceuticals | Stasiv Y.,Anthera Pharmaceuticals | And 2 more authors.
Journal of the American College of Cardiology | Year: 2010

Objectives The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary syndrome patients. Background Secretory phospholipase A2 (sPLA2) represents a family of proatherogenic enzymes that hydrolyze lipoprotein phospholipids, increasing their affinity for intimal proteoglycans; contribute to cholesterol loading of macrophages by nonscavenger receptor mediated pathways; and activate inflammatory pathways. In prospective studies, high sPLA2-IIA levels predicted major adverse cardiovascular events in acute coronary syndrome (ACS) and stable coronary heart disease patients. Methods This randomized, double-blind, prospective controlled clinical trial (phase 2B) was designed to investigate the effects of sPLA2 inhibition with varespladib 500 mg daily versus placebo as adjunctive therapy to atorvastatin 80 mg daily on biomarkers (low-density lipoprotein cholesterol [LDL-C], high-sensitivity C-reactive protein [hsCRP], and sPLA2-IIA levels), major adverse cardiovascular events (unstable angina, myocardial infarction, death), and safety. In all, 625 ACS subjects were randomized within 96 h of the index event and treated for a minimum of 6 months. Results After 8 weeks (primary efficacy end point), varespladib/atorvastatin reduced mean LDL-C levels from baseline by 49.6% compared with 43.4% with placebo/atorvastatin (p = 0.002). Respective 8-week median reductions in sPLA2-IIA levels were 82.4% and 15.6% (p < 0.0001), and hsCRP levels were lowered by 75.0% and 71.0% (p = 0.097). At 24 weeks, respective reductions with varespladib and placebo were as follows: LDL-C 43.5% versus 37.6% (p < 0.05), hsCRP 79.8% versus 77.0% (p = 0.02), and sPLA2-IIA 78.5% versus 6.4% (p < 0.0001). Major adverse cardiovascular events were not different from placebo 6 months post-randomization (7.3% varespladib vs. 7.7% placebo). No treatment differences in elevated liver function studies on >1 occasion were observed. Conclusions Varespladib therapy effectively reduced LDL-C and inflammatory biomarkers in ACS patients treated with conventional therapy including atorvastatin 80 mg daily. There were no treatment differences in clinical cardiovascular events. (FRANCIS [Fewer Recurrent Acute Coronary Events With Near-Term Cardiovascular Inflammation Suppression]-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes; NCT00743925). © 2010 American College of Cardiology Foundation. Source

Discover hidden collaborations